Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06045026
Other study ID # 300058
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 21, 2023
Est. completion date April 25, 2024

Study information

Verified date April 2024
Source HALEON
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the impact of long-term use of a desensitizing toothpaste containing 0.454 percent (%) stannous fluoride (SnF2) on oral health related quality of life (OHrQoL) in a population of self-reported dentin hypersensitivity (DH) sufferers. Data generated will provide real world information on the DH experience and DH management with a daily use anti-sensitivity treatment.


Description:

This will be a decentralized, prospective, 24-week, monadic design, open label, study in a DH population. The study will evaluate changes in OHrQoL in participants with self-reported DH symptoms over 24 weeks of use of a DH treatment (anti-sensitivity toothpaste). OHrQoL will be measured using a validated questionnaire, the Dentin Hypersensitivity Experience Questionnaire (DHEQ-48), completed by study participants at Baseline, and Weeks 4, 8, 12, 16, 20, 24.


Recruitment information / eligibility

Status Completed
Enrollment 536
Est. completion date April 25, 2024
Est. primary completion date April 25, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Participant who has provided consent indicating they have been informed of all pertinent aspects of the study. - All genders who, at the time of screening, are aged between 18 and 65 years (inclusive). - Participant who is willing to complete all the assigned activities. - Participant who is able to independently complete all the assigned activities on their smart devices. - Participant who has tooth sensitivity (self-reported symptoms). Exclusion Criteria: - Participant whose sensitivity could be caused by other factors or clinical pathology than DH, as self-reported on the screening questionnaire, which include: 1. Participant who has been/is on multiple prescription medications to treat severe acid reflux on a regular basis or has had surgery for acid reflux. 2. Participant with full or partial denture(s). 3. Participant who has undergone treatment for periodontal or gum disease within 6 months of screening or is currently undergoing treatment for periodontal or gum disease. 4. Participant who has been informed by a Dental Health Care Professional (DHCP) that they have active periodontitis. 5. Participant who has been informed by a DHCP that they have active caries. 6. Participant with any chronic and/or severe painful health condition(s) which lead to regular use of pain relief medications (more than 3 days a week). - Participant with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Stannous fluoride
Anti-sensitivity toothpaste containing 0.454% Stannous Fluoride

Locations

Country Name City State
United States ObvioHealth Virtual Site New York New York

Sponsors (1)

Lead Sponsor Collaborator
HALEON

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline in DHEQ Total Score (Section 2, Question [Q]1-34) at Weeks 4, 8, 12, 16, 20 and 24 The DHEQ is a condition-specific measure of OHrQoL in relation to DH which contains total 34 questions in section 2, each with the scale ranging from 1 (strongly disagree) to 7 (strongly agree). Thus, the total score ranges from 34 to 238, where lower score indicates improvement in the symptoms. Change from Baseline is defined as score at indicated post-Baseline timepoint minus score at Baseline. Baseline and Weeks 4, 8, 12, 16, 20, 24
Primary Change from Baseline in DHEQ Restrictions Domain (Q1-4) Score at Weeks 4, 8, 12, 16, 20 and 24 Restrictions domain in DHEQ evaluates the ways in which any sensations in teeth affect participant's daily life. This contains 4 questions each with the scale ranging from 1 (strongly disagree) to 7 (strongly agree). Thus, the total score ranges from 4 to 28, where lower score indicates improvement in the symptoms. Change from Baseline is defined as score at indicated post-Baseline timepoint minus score at Baseline. Baseline and Weeks 4, 8, 12, 16, 20, 24
Primary Change from Baseline in DHEQ Adaptation Domain Score (Q5-16) at Weeks 4, 8, 12, 16, 20 and 24 Adaptation domain in DHEQ evaluates 'the ways in which the sensations in teeth have forced participants to change things in their daily life'; 'things they do in their daily life to avoid experiencing the sensations in their teeth'. This contains 12 questions each with the scale ranging from 1 (strongly disagree) to 7 (strongly agree). Thus, the total score ranges from 12 to 84, where lower score indicates improvement in the symptoms. Change from Baseline is defined as score at indicated post-Baseline timepoint minus score at Baseline. Baseline and Weeks 4, 8, 12, 16, 20, 24
Primary Change from Baseline in DHEQ Social Impact Domain (Q17-21) Score at Weeks 4, 8, 12, 16, 20 and 24 Social Impact domain in DHEQ evaluates the way the sensations affect participants when they are with other people or in certain situations. This contains 5 questions each with the scale ranging from 1 (strongly disagree) to 7 (strongly agree). Thus, the total score ranges from 5 to 35, where lower score indicates improvement in the symptoms. Change from Baseline is defined as score at indicated post-Baseline timepoint minus score at Baseline. Baseline and Weeks 4, 8, 12, 16, 20, 24
Primary Change from Baseline in DHEQ Emotional Impact Domain (Q22-29) Score at Weeks 4, 8, 12, 16, 20 and 24 Emotional Impact Domain in DHEQ evaluates the way the sensations in participant's teeth make them feel. This contains 8 questions each with the scale ranging from 1 (strongly disagree) to 7 (strongly agree). Thus, the total score ranges from 8 to 56, where lower score indicates improvement in the symptoms. Change from Baseline is defined as score at indicated post-Baseline timepoint minus score at Baseline. Baseline and Weeks 4, 8, 12, 16, 20, 24
Primary Change from Baseline in DHEQ Identity Domain (Q30-34) Score at Weeks 4, 8, 12, 16, 20 and 24 Identity Domain in DHEQ evaluates what the sensations in participant's teeth mean for them. This contains 5 questions each with the scale ranging from 1 (strongly disagree) to 7 (strongly agree). Thus, the total score ranges from 5 to 35, where lower score indicates improvement in the symptoms. Change from Baseline is defined as score at indicated post-Baseline timepoint minus score at Baseline. Baseline and Weeks 4, 8, 12, 16, 20, 24
Secondary Change from Baseline in Impact on Everyday Life (Section 1, Q1-3) at Weeks 4, 8, 12, 16, 20 and 24 DHEQ section 1 consist of 3 questions about teeth sensation and its impact on everyday life. Participants will score Q1 (how intense are the sensations?) on a scale of 1 (not at all intense) to 10 (worst imaginable); Q2 (how bothered are you by any sensations?) on a scale of 1 (not at all bothered) to 10 (extremely bothered); Q3 (how well can you tolerate sensations?) on a scale of 1 (can easily tolerate) to 10 (can't tolerate at all). The total score for each question ranging from 3 to 30; where lower score indicates less sensitivity and less impact on everyday life. Change from Baseline is defined as score at indicated post-Baseline timepoint minus score at Baseline. Baseline and Weeks 4, 8, 12, 16, 20, 24
Secondary Change from Baseline in Global Oral Health (Section 2, Q35) Score at Weeks 4, 8, 12, 16, 20 and 24 Global Oral Health will be evaluated using a single question which asks about overall health of participant's mouth, teeth, and gums. The scale ranges from 1 (excellent) to 6 (Very poor), where lower score indicates improvement in the symptoms. Change from Baseline is defined as score at indicated post-Baseline timepoint minus score at Baseline. Baseline and Weeks 4, 8, 12, 16, 20, 24
Secondary Change from Baseline in Effect on Life Overall (Section 2, Q36-39) Score at Weeks 4, 8, 12, 16, 20 and 24 Effect on Life will be evaluated using 4 questions which asks how much the sensations in teeth affect participant's life overall. The scale ranges from 0 (not at all) to 4 (Very much), where lower score indicates improvement in the symptoms. Change from Baseline is defined as score at indicated post-Baseline timepoint minus score at Baseline. Baseline and Weeks 4, 8, 12, 16, 20, 24
Secondary Percentage of Participants who 'Agree' (Score 5-7) With Each Item (statement) in the 5 DHEQ Domains (Section 2, Q1-34) at Baseline and Week 24 The DHEQ consists of 5 domains namely- Restrictions, Adaptation, Social Impact, Emotional Impact and Identity with total 34 questions about the ways in which any sensations in teeth affect participants in their daily life. The scale ranges from 1(strongly disagree) to 7(strongly agree) and scores 5 to 7 indicates agreement with the statement mentioned in the question, where 5=Agree a little, 6=Agree and 7=Strongly agree. Baseline and Week 24
Secondary Change from Baseline in Numeric Pain Rating Scale (NPRS) Score at Weeks 1, 2, 4, 8, 12, 16, 20 and 24 NPRS is the 11-point segmented numeric version of a Visual Analogue Scale from which the respondent selects the score (0-10) that best reflects the intensity of their pain, where 0=no pain and 10=worst possible pain. Higher scores are indicative of greater pain intensity. Change from Baseline is defined as score at indicated post-Baseline timepoint minus score at Baseline. Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24
Secondary Satisfaction Numeric Rating Scale (NRS) Score at Week 24 Participants will rate their satisfaction with the DH treatment using NRS. It is an 11-point ordinal scale used to assess satisfaction with the overall management of the condition for which the individual sought help from treatment. It ranges from 0 (completely dissatisfied) to 10 (completely satisfied), with higher scores indicative of greater satisfaction. Week 24
Secondary Oral Hygiene Questionnaire (OHQ) Responses at Baseline Participants will describe their oral hygiene habits at Baseline by completion of an OHQ. Baseline
See also
  Status Clinical Trial Phase
Completed NCT02753075 - A Study in Dentinal Hypersensitivity (DH) Participants to Assess the Efficacy of an Occluding Dentifrice. N/A
Completed NCT02861664 - Assessment of the Efficacy of an Experimental Occlusion Technology Dentifrice in Dentinal Hypersensitivity N/A
Completed NCT02542943 - Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Dentinal Hypersensitivity N/A
Completed NCT02226562 - Clinical Study Investigating the Efficacy of a Mouthwash in Providing Long Term Relief From Dentinal Hypersensitivity Phase 2
Completed NCT02919202 - Clinical Trial to Compare the Efficacy of a Fluoride Gel and a Dental Bonding Agent in Treatment of Tooth Sensitivity N/A
Not yet recruiting NCT04485299 - Clinical Assessment of Bifluorid 10 vs Varnish Fluoride on The Exposed Hypersensitive Cervical Dentin in Adult Patient Phase 2/Phase 3
Completed NCT02931734 - Assessment of Different Protocols for Cervical Dentin Hypersensitivity Treatment N/A
Completed NCT02923895 - To Investigate the Efficacy of an Occluding Dentifrice in Dentinal Hypersensitivity (DH) Phase 4
Withdrawn NCT03361774 - A Clinical Method Development Study to Characterise The Efficacy of a Dentifrice For The Relief Of Dentin Hypersensitivity Phase 2
Completed NCT02924350 - The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity (DH) N/A
Completed NCT05083052 - Propolis in Reducing Dentin Hypersensitivity N/A
Active, not recruiting NCT06150573 - A Study Assessing the Effects of an Experimental Dentifrice in Maintaining Tooth Color Following Tooth Bleaching N/A
Completed NCT02937623 - To Evaluate the Efficacy of an Experimental Dissolvable Strip in Rapidly Relieving Dentinal Hypersensitivity (DH) N/A
Completed NCT02612064 - The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity N/A
Completed NCT02293044 - A Study to Evaluate the Safety and Efficacy of an Oxalate Strip on Adjacent Teeth With Dentinal Hypersensitivity N/A
Completed NCT02128633 - Effectiveness of a Homecare Dentin Hypersensitivity Gel Phase 2/Phase 3
Completed NCT03310268 - A Clinical Study to Evaluate a Stannous Fluoride Toothpaste for the Relief of Dentinal Hypersensitivity N/A
Completed NCT05750745 - A Clinical Study to Evaluate the Efficacy of a Stannous Fluoride Toothpaste for the Relief of Dentine Hypersensitivity in a Chinese Population N/A
Not yet recruiting NCT06417580 - Effect of Pregabalin Gel in Controlling Cervical Dentin Hypersensitivity Phase 2
Completed NCT02752958 - Impact of Long Term Management of Dentine Hypersensitivity (DH) With a Daily Use Anti-sensitivity Toothpaste on the Quality of Life Related to Oral Health N/A